PDGFRB and neoplasm: Recurrent tumors after denosumab treatment displayed a similar intensity of PDGFRβ immunostaining as it could be observed in the primary biopsies which means, the intensity of PDGFRβ immunostaining in stroma/tumor cells was restored/decreased (Table 2) (Figure 3B).